Showing 8261-8270 of 8647 results for "".
- Telemedicine Eye Screenings Help Detect Glaucomahttps://modernod.com/news/telemedicine-eye-screenings-help-detect-glaucoma/2476356/A low-cost program using technicians to conduct telemedicine eye screenings can help detect glaucoma in underserved populations, according to new research, as reported by Reuters. The study targeted high-risk individuals in poorer a
- Raindrop Near Vision Inlay Recalledhttps://modernod.com/news/fda-issues-recall-of-raindrop-near-vision-inlay/2476350/A Class I recall of the Raindrop near vision inlay has been issued due to an increased risk of corneal haze, according to the FDA. The owner of the Raindrop inlay, RVO 2.0, doing business as Optics Medical, issued the recall after an October warning letter from the FDA cited a post-approva
- FDA Chief Scott Gottlieb to Resignhttps://modernod.com/news/fda-chief-scott-gottlieb-to-resign/2476349/FDA Commissioner Scott Gottlieb is resigning, ending a tenure at the agency where he approved a flood of new drugs and cheaper copycat pills, and pushed for sharp curbs on e-cigarette use to halt what he called an epidemic of youth use, according to a Bloomberg
- MacuLogix Raises $38.7 Million in Series D Financing to Support Growthhttps://modernod.com/news/maculogix-raises-38-7-million-in-series-d-financing-led-by-vivo-capital/2479587/MacuLogix has completed a Series D round of financing totaling $38.7 million to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx
- Macula May Not Benefit From a Blue-Light Filtering Intraocular Lenshttps://modernod.com/news/macula-may-not-benefit-from-a-blue-light-filtering-intraocular-lens/2476346/Inserting a blue light-filtering IOL during cataract surgery may not benefit the macula, researchers say, according to a Reuters report. “It has been suggested that IOLs that selectively attenuate short wavelength visible l
- Penetrating Keratoplasty Effective for Corneal Complications of Shingleshttps://modernod.com/news/penetrating-keratoplasty-effective-for-corneal-complications-of-shingles/2479592/Even in eyes with preoperative risks, penetrating keratoplasty (PKP) can achieve favorable results for the corneal complications of herpes zoster ophthalmicus (HZO), researchers say, as reported by Reuters. “What we learned is
- Pharmaceutical Executives Field Questions at US Senate Hearing Over Drug Pricinghttps://modernod.com/news/pharmaceutical-executives-field-questions-at-us-senate-hearing-over-drug-pricing/2476258/CEOs and senior executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson appeared before the US Senate Finance Committee on Tuesday to testify about the high cost of drugs in the country. The executives, who continued to blame pharmacy
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- WSJ: Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billionhttps://modernod.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/Swiss pharmaceutical company Roche is nearing a deal to buy Philadelphia-based biotechnology company Spark Therapeutics, according to a report in the Wall Street Journal